

What is claimed is:

1. A substantially purified antibody comprising a variable heavy (VH) complementarity determining region (CDR)1 having an amino acid sequence of SEQ ID NO:49 or 73, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
2. A substantially purified antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50 or 74, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
3. A substantially purified antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51 or 75, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
4. A substantially purified antibody comprising a variable light (VL) CDR1 having an amino acid sequence of SEQ ID NO:52 or 76, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
5. A substantially purified antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53 or 77 antibody immunospecifically binds to a TANGO 268 antigen.
6. A substantially purified antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54 or 78, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
7. The antibody of claim 1 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 74.
8. The antibody of claim 1 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63, 69 or 75.

9. The antibody of claim 1 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 74 and a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63, 69 or 75.

10. The antibody of claim 1 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.

11. The antibody of claim 1 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.

12. The antibody of claim 1 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

13. The antibody of claim 1 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

14. The antibody of claim 7, 8 or 9 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.

15. The antibody of claim 7, 8 or 9 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.

16. The antibody of claim 7, 8 or 9 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

17. The antibody of claim 7 or 8 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

18. The antibody of claim 9 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

19. The antibody of claim 2 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 75.

20. The antibody of claim 2 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.

21. The antibody of claim 2 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.

22. The antibody of claim 2 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 73.

23. The antibody of claim 2 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

24. The antibody of claim 19 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

25. The antibody of claim 3 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.

26. The antibody of claim 3 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.

27. The antibody of claim 3 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

28. The antibody of claim 3 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.

29. A Fab fragment of a mouse monoclonal antibody produced by the mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

30. An antibody that competes for binding to a TANGO 268 antigen with the scFv clone A4, A9, A10 or C3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.

31. An antibody that competes for binding to a TANGO 268 antigen with the mouse monoclonal antibody produced by the mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

32. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a monoclonal antibody.

33. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a human antibody.

34. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a humanized antibody.

35. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a Fab fragment.

36. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is an scFv.

37. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31, wherein the antibody is conjugated to a therapeutic or drug moiety.

38. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31, wherein the antibody is conjugated to a detectable substance.

39. A pharmaceutical composition comprising an antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31, and a pharmaceutically acceptable carrier.

40. A pharmaceutical composition comprising an antibody as in claim 37, and a pharmaceutically acceptable carrier.

41. A kit comprising an antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31 and instructions for use, in one or more containers.

42. A kit comprising an antibody as in claim 38 and instructions for use, in one or more containers.